The trading price of VistaGen Therapeutics Inc. (NASDAQ:VTGN) closed higher on Tuesday, July 20, closing at $2.75, 1.48% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $2.63 and $2.79. In examining the 52-week price action we see that the stock hit a 52-week high of $3.55 and a 52-week low of $0.56. Over the past month, the stock has lost -4.84% in value.
VistaGen Therapeutics Inc., whose market valuation is $543.56 million at the time of this writing, is expected to release its quarterly earnings report Feb 11, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.05 per share this quarter, however they have predicted annual earnings per share of -$0.26 for 2022 and -$0.37 for 2023. It means analysts are expecting annual earnings per share growth of 46.90% this year and -42.30% next year.
Analysts have forecast the company to bring in revenue of $380k for the current quarter, with the likely lows of $300k and highs of $440k. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2022 is $1.19 million. The company’s revenue is forecast to grow by 9.30% over what it did in 2022.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of VistaGen Therapeutics Inc. 2 upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest VTGN has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned VTGN a recommendation rating is 4. Out of them, 0 rate it a Hold, while 3 recommend Buy, whereas 1 assign an Overweight rating. 0 analyst(s) have tagged VistaGen Therapeutics Inc. (VTGN) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that VTGN’s price is currently -6.56% off the SMA20 and 0.50% off the SMA50. The RSI metric on the 14-day chart is currently showing 44.81, and weekly volatility stands at 7.30%. When measured over the past 30 days, the indicator reaches 8.12%. VistaGen Therapeutics Inc. (NASDAQ:VTGN)’s beta value is currently sitting at 0.93, while the Average True Range indicator is currently displaying 0.21. With analysts defining $5.00-$9.00 as the low and high price targets, we arrive at a consensus price target of $7.50 for the trailing 12-month period. The current price is about -81.82% off the estimated low and -227.27% off the forecast high, based on this estimate. Investors will be thrilled if VTGN’s share price rises to $8.00, which is the median consensus price. At that level, VTGN’s share price would be -190.91% below current price.
To see how VistaGen Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: VTGN stock’s performance was 1.48% in the latest trading, and 272.63% in the past year, while Iovance Biotherapeutics Inc. (IOVA) has traded 3.62% on the day and positioned -24.98% lower than it was a year ago. VistaGen Therapeutics Inc. has a P/E ratio of 0. Also in last trading session, the S&P 500 Index has surged 1.52%, while the Dow Jones Industrial also saw a positive session, up 1.62% on the day.
An evaluation of the daily trading volume of VistaGen Therapeutics Inc. (NASDAQ:VTGN) indicates that the 3-month average is 2.99 million. However, this figure has increased over the past 10 days to an average of 1.53 million.
Currently, records show that 144.88 million of the company’s shares remain outstanding. The insiders hold 0.10% of outstanding shares, whereas institutions hold 60.70%. The stats also highlight that short interest as of May 27, 2021, stood at 6.74 million shares, resulting in a short ratio of 1.91 at that time. From this, we can conclude that short interest is 3.55% of the company’s total outstanding shares. It is noteworthy that short shares in May were up slightly from the previous month’s figure, which was 6.31 million. However, since the stock’s price has seen 41.75% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.